For research use only
| Cat No. | ABC-TC0213 |
| Product Type | Human Lung Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Small Cell Cancer |
| Product Code | DMS-153; DMS153 |
DMS 153 ,human small cell lung carcinoma line from liver metastasis, widely used in oncology, drug resistance, therapeutic studies, and drug discovery.
DMS 153 is a human small cell lung carcinoma (SCLC) cell line derived from the liver metastasis tissue of a 44-year-old Caucasian male patient diagnosed with metastatic SCLC. This cell line exhibits epithelial-like morphology and adherent growth with a doubling time of approximately 48–72 hours. DMS 153 harbors a TP53 mutation (c. 463A>C; p. Thr155Pro) and secretes bioactive peptides, including calcitonin, adrenocorticotropic hormone, and calcitonin gene-related peptide (CGRP). It expresses characteristic surface markers such as Leu7(CD57), My23, and ITGAM(CD11b) and demonstrates tumorigenic potential in immunodeficient mice, forming subcutaneous tumors upon xenotransplantation. DMS 153 shows metastatic origin and peptide hypersecretion profile make it valuable for studying SCLC paraneoplastic syndromes and immune interactions.
| Product Code | DMS-153; DMS153 |
| Species | Human |
| Cat.No | ABC-TC0213 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Semi-adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Small Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
DMS 153 cell line serves as a key experimental model in the study of small cell lung carcinoma (SCLC), an aggressive and highly metastatic cancer subtype. Researchers widely utilize this cell line to identify novel diagnostic and prognostic biomarkers for SCLC and exploring the neuroendocrine phenotype associated with paraneoplastic syndromes. The cell line is also instrumental in evaluating anticancer therapeutics, particularly those targeting apoptotic pathways, and in testing immunomodulatory strategies. Its peptide secretion profile and tumorigenic behavior make it suitable for investigations into tumor-host signaling, drug resistance mechanisms and effective treatment approaches for SCLC.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
